The Life Sciences Virtual Investor Forum, a B2i Digital Featured Conference co-hosted by Virtual Investor Conferences and Zacks Small-Cap Research, will take place over two days on June 24 and 25, 2026. The event offers investors direct access to management teams from over 20 public companies spanning biotechnology, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health.
B2i Digital, as the Official Marketing Partner, brings the forum into its ecosystem, anchored by a distribution and media engine that drives qualified investors to the presentations and one-on-one meetings. Before, during, and after the event, B2i amplifies the event across its platform, putting these life sciences companies in front of a proprietary network of more than 1.7 million retail and institutional market participants. The same visibility engine has supported more than 115 investor conferences.
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, prepares independent company-sponsored research and related content for distribution across investor and media channels. Its team of life sciences analysts supports the forum as co-host.
Each company has 30 minutes for a live presentation and Q&A. One-on-one meeting requests are available through the VIC site, with replays available on B2i Digital and OTC Markets YouTube channels.
“Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides,” said David Shapiro, Chief Executive Officer of B2i Digital.
Day One on June 24 includes presentations from Protalix BioTherapeutics, MetaVia Inc., CytoSorbents Corporation, PetVivo Holdings Inc., Jaguar Health, Inc., Reviva Pharmaceuticals Holdings, Inc., and 4DMedical Ltd. Day Two on June 25 features Prostatype Genomics AB, Abingdon Health plc, Innovotech, Inc., Lakewood-Amedex Biotherapeutics Inc., Nasus Pharma Ltd., Kelyniam Global, Inc., IMUNON, Inc., Promino Nutritional Sciences Inc., Envoy Medical Inc., Coiled Therapeutics plc, Aspire Biopharma Holdings Inc., Rocket Doctor AI Inc., Phio Pharmaceuticals Corp., aTyr Pharma, Inc., and NuFarm Ltd.
To request one-on-one meetings with management, visit the Axle Access page. For more details, see the B2i Digital event page. Registration and company profiles are available at the Virtual Investor Conferences registration site.
The forum underscores the growing demand for efficient investor access to life sciences innovation, particularly as companies navigate clinical milestones, regulatory pathways, and market adoption. By combining live presentations with independent research, the event aims to facilitate informed investment decisions across a broad spectrum of therapeutic and technological areas.
